60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies o

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectiou

Related Keywords

United States , Singapore , Central School , Washington , Monash , South Australia , Australia , Melbourne , Victoria , Canada , Australian , American , Geoff Dow , Anton Peleg , Patrick Gaynes , Sheilaa Burke , Degrees Pharmaceuticals Inc , Bp Australia Pty Ltd , National Institutes Of Health , Exchange Commission , Degrees Pharmaceuticals , National Institute Of Allergy , Monash University , Drug Administration , Centers For Disease , Knight Therapeutics Inc , United States Department Of Defense , Professor At Central Clinical School , Walter Reed Army Institute Of Research , Australia Pty Ltd , Pharmaceuticals Chief Executive Officer , Professor Anton Peleg , Central Clinical School , New Infections , National Institute , Infectious Diseases , National Institutes , Disease Control , Walter Reed Army Institute , Important Safety Information , Important Safety , Adverse Reactions , Specific Populations , United States Department , Securities Litigation Reform Act , Annual Report , Quarterly Reports , Candida Auris , Afenoquine , Candida Spp , Pharmaceuticals , Malaria , Fungal Infection , Tauris , 80 Degrees ,